Perioperative Durvalumab Continues to Show Clinical Benefit in Patients with Resectable Stage IIA to IIIB NSCLC By Ogkologos - September 17, 2026 9 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a second planned interim analysis of the AEGEAN study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the European Parliament’s (EP) Call for a Sustainable Cancer Workforce to Deliver Quality Care for Patients with Cancer ESMO Welcomes the Inclusion of Tobacco Provisions in European Parliament’s Report on Cardiovascular Diseases and Calls for Additional Measures to Prevent Cancer FDA Approves Zidesamtinib for ROS1-positive Non-Small Cell Lung Cancer MOST POPULAR HGTV Star Hilary Farr Shares Breast Cancer Battle December 16, 2021 What to Expect During Recovery From a Bone Marrow Transplant: An... June 20, 2023 Could a Vaccine Prevent Colorectal Cancer in People with Lynch Syndrome? April 19, 2019 Can Eating Grilled or Charred Foods Cause Cancer? January 10, 2023 Load more HOT NEWS Wine Racks and the Mystery of Survival ESMO-WHO Collaboration in Kazakhstan Yields Evidence-Based Approach for Closing the Gaps... Open Enrollment for 2022 Affordable Care Act Plans is Here! Women Under 35 More Likely to Have Their Breast Cancer Spread
